Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | Aplastic Anemia & MDS International Foundation
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Clinical Trial: NCT03066648

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine in AML and high risk MDS patients, and to identify recommended doses for future studies.

Status: 
Recruiting
Study Date: 
Tue, 02/28/2017 to Thu, 04/01/2021
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Decitabine Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation. Other Name: 5-aza-2'-deoxycytidine Drug: PDR001 PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2. Drug: MBG453 MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).